By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

Ben Trotman, diagnosed with terminal glioblastoma in 2022, experienced a complete remission after receiving ipilimumab before ...

New RNA vaccine shows promise in turning resistant tumors into immunotherapy targets. Study offers hope for more effective, ...

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...

A man who was diagnosed with the deadliest form of brain cancer has shown no signs of the disease after being treated with ...

Man with deadly glioblastoma shows no signs of disease after taking experimental immunotherapy drug ipilimumab, inspiring a ...

Glioblastoma is widely considered the deadliest form of brain cancer, killing over 10,000 Americans each year.

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

The 81,000-square-foot facility will enhance the health system's cancer care offerings in the UK, with completion expected in ...

"If immunotherapy eliminates most of the tumor before surgery, then we have sufficiently trained the immune system for an antitumor response, which minimizes the possibility of recurrence," said lead ...